Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
Cognitive and affective disorders associated to HIV infection in the HAART era. Findings from the NeuroICONA Study / F. Starace, L. Bartoli, M.S. Aloisi, A. Antinori, P. Narciso, G. Ippolito, L. Ravasio, M.C. Moioli, D. Vangi, L. Gennero, O. Coronado, A. Giacometti, S. Nappa, M.L. Perulli, V. Montesarchio, A. La Gala, F. Ricci, L. Cristiano, M. De Marco, C.M. Izzo, P. Pezzotti, A. d’Arminio Monforte. - In: ACTA PSYCHIATRICA SCANDINAVICA. - ISSN 0001-690X. - 106:1(2002), pp. 20-26. [10.1034/j.1600-0447.2002.02289.x]
Cognitive and affective disorders associated to HIV infection in the HAART era. Findings from the NeuroICONA Study.
A. d’Arminio Monforte
2002
Abstract
Objective: To assess the natural story of HIV-associated affective and cognitive disorders and the relationship with clinical, pharmacological, immunological and behavioural factors. Method: A total of 395 HIV-positive patients, naive to Highly Active Antirectroviral therapy (HAART), with no severe psychiatric disorders have been enrolled in the Neuro-ICONA Study. All participants were administered a comprehensive data collection instrument including an addiction behaviour survey, a medical problem list, a psychiatric assessment, a validated neuropsychological test battery. Results: The global prevalence of cognitive impairment and of prominent depressive symptomatology were 17.9 and 15.5%, respectively. A significant difference in the prevalence of prominent depressive symptomatology was observed between patients in HAART and those not taking HAART(14.1 vs. 23.8%; P = 0.05). Conclusion: Depressive and cognitive disorders affect a substantial proportion of HIV-seropositive subjects. The prevalence of prominent depressive symptomatology appears to significantly vary in relationship to the therapeutic protocol.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
